A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (C11005)

Trial Profile

A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (C11005)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms PhaseOut DMD
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 14 Jun 2017 According to a Summit Therapeutics media release, in May 2017 the company has received the necessary regulatory approvals for the extension phase.
    • 14 Jun 2017 According to a Summit Therapeutics media release, top-line data from the complete 48-week clinical trial are expected in the third quarter of 2018.
    • 14 Jun 2017 According to a Summit Therapeutics media release, provision has been made for patients in the trial to remain on ezutromid beyond the initial 48-weeks of the trial, which will allow monitoring of safety and efficacy data related to longer-term dosing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top